The US FDA appears to be adding onto its planned slew of disease-specific guidances, with Commissioner Scott Gottlieb announcing that the agency will be releasing "a suite" of such guidances on the development of specific gene therapy documents.
Testifying before the Senate Committee on Health, Education, Labor and Pensions Dec
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?